Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo Chinese For Medical Students & Physicians A complete 20-lesson, 300-page Chinese course with a companion app in 21 languages — free forever. Download the free PDF: Amedeo Chinese PDF

Autoimmune Disorders

Free Subscription Articles published in J Nephrol Retrieve available abstracts of 101 articles: HTML format

Single Articles

September 2026
1. YANG C, Chen P, Xiong J
   Finerenone in IgA nephropathy: A Systematic Review of Real-world Studies.
   J Nephrol. 2026 Sep 30:aajag228. doi: 10.1093.
   PubMed    
   
   
   
2. HUANG Z, Ma J, Bian X
   Clinical Significance of Increased Degree of Hematuria in Patients affected by IgA Nephropathy.
   J Nephrol. 2026 Sep 7:aajag241. doi: 10.1093.
   PubMed     Abstract available
   
   
   
3. GUZZO G, Al-Gobari M, Jaques C, Teta D, et al
   Crescents in native kidney biopsies from patients with IgA nephropathy and the risk of recurrence after kidney transplantation: a retrospective cohort study, systematic literature review and meta-analysis of observational studies.
   J Nephrol. 2026 Sep 4:aajag169. doi: 10.1093.
   PubMed     Abstract available
   
   
   August 2026
4. POZZI C, Baragetti I, Barruscotti A, Del Vecchio L, et al
   The outcome of IgAN: a time of reflection in the perspective of new opportunities.
   J Nephrol. 2026;39:712-716.
   PubMed     Abstract available
   
   
   
5. KUANG QH, Yang M, Xia W, Yan SJ, et al
   Clinicopathological features and risk factor analysis of pediatric IgA vasculitis with nephritis associated with acute kidney injury.
   J Nephrol. 2026;39:758-767.
   PubMed     Abstract available
   
   
   
6. SAKODA K, Mizuno K, Shinkawa K, Hayashi A, et al
   Factors associated with disease severity in adults with acute glomerulonephritis: a descriptive retrospective cohort study.
   J Nephrol. 2026 Aug 20:aajag229. doi: 10.1093.
   PubMed     Abstract available
   
   
   
7. AL JURDI A, El Mouhayyar C, Yatim K, Efe O, et al
   Anti-PLA2R antibody levels are associated with thromboembolism risk in individuals with membranous nephropathy and hypoalbuminemia.
   J Nephrol. 2026 Aug 14:aajag121. doi: 10.1093.
   PubMed     Abstract available
   
   
   
8. CALVISI S, Baviera M, Torrigiani G, Fortino I, et al
   Renal outcomes and all-cause death in patients with systemic lupus erythematosus: insights from a population-based study in Northern Italy.
   J Nephrol. 2026 Aug 13:aajag138. doi: 10.1093.
   PubMed     Abstract available
   
   
   
9. BERTOLA R, Silvagni E, Scichilone L, Pollicelli E, et al
   Voclosporin for the treatment of lupus nephritis flares in patients with inadequate response to mycophenolate mofetil and belimumab: a case series.
   J Nephrol. 2026 Aug 12:aajag126. doi: 10.1093.
   PubMed     Abstract available
   
   
   
10. ONOUE K, Okubo A, Yoshida M, Takahashi A, et al
    Association between hematuria remission at 6 months and subsequent kidney outcomes in IgA nephropathy.
    J Nephrol. 2026 Aug 12:aajag223. doi: 10.1093.
    PubMed     Abstract available
    
    
    
11. FETOUH MG, Sabry A, Fouda MA, Abdulrahim M, et al
    Repeat kidney biopsy unmasks the transition from active inflammation to irreversible damage in lupus nephritis: longitudinal outcomes from a single-center cohort in Egypt.
    J Nephrol. 2026 Aug 6:aajag097. doi: 10.1093.
    PubMed     Abstract available
    
    
    
12. PAUL SP, Roy S, Matthai SM, Gopinathan V, et al
    Histopathologic and clinical spectrum of IgA nephropathy coexisting with other glomerulopathies; addressing the diagnostic challenges. Experience from a tertiary care center.
    J Nephrol. 2026 Aug 5:aajag067. doi: 10.1093.
    PubMed     Abstract available
    
    
    
13. JING S, Yang X, Li S, Dong L, et al
    Predicting the risk of lupus nephritis based on a nomogram in patients with childhood-onset systemic lupus erythematosus.
    J Nephrol. 2026 Aug 4:aajaf003. doi: 10.1093.
    PubMed     Abstract available
    
    
    June 2026
14. SHOU J, Su F, Wang Y, Liao Y, et al
    Beclin-1/LC3B regulation of podocyte autophagy in IgA nephropathy via PI3K/AKT signaling.
    J Nephrol. 2026 Jun 10:aajag006. doi: 10.1093.
    PubMed     Abstract available
    
    
    
15. JAIN A, Pabba M, Pal A, Beers K, et al
    Tumor necrosis factor inhibitor-associated IgA nephropathy in the setting of Behcet's disease: Lessons for the clinical nephrologist.
    J Nephrol. 2026 Jun 8:aajag053. doi: 10.1093.
    PubMed    
    
    
    
16. PRAKASH TS, Kamat N, Janardhanan JJ
    Immune complex-mediated membranoproliferative glomerulonephritis following scabies infestation in a child: a rare association.
    J Nephrol. 2026 Jun 5:aajag062. doi: 10.1093.
    PubMed     Abstract available
    
    
    
17. KLEIN M, Roberts V, Javaid MM
    Immunoglobulin A nephropathy-novel insights in long-term outcomes and pathophysiology leading to international guideline modification and new emerging therapies.
    J Nephrol. 2026;39:37-49.
    PubMed     Abstract available
    
    
    
18. KRAMER S, Vogt K, Busch M, Schmitt T, et al
    Risk stratification for renal outcomes in ANCA-associated vasculitides using established scores and histopathological criteria.
    J Nephrol. 2026;39:179-187.
    PubMed     Abstract available
    
    
    May 2026
19. MA XJ, Liu JX, Yang WG, Sun A, et al
    Telitacicept for refractory IgA nephropathy: a case series.
    J Nephrol. 2026 May 20:aajag012. doi: 10.1093.
    PubMed     Abstract available
    
    
    
20. NGUYEN MK, Chou A, Ramachandran R, Kurien AA, et al
    Complementary and alternative medicine-associated membranous nephropathy: a systematic review.
    J Nephrol. 2026 May 18:aajaf036. doi: 10.1093.
    PubMed     Abstract available
    
    
    April 2026
21. DOS SANTOS BORGES R, Lara Santos R, Haikal de Paula L, Borges Martins JM, et al
    Efficacy, safety, and biomarker changes of B-cell activating factor and A proliferation-inducing ligand-targeted therapies in IgA nephropathy: a systematic review and meta-analysis of randomized controlled trials.
    J Nephrol. 2026 Apr 22:aajaf002. doi: 10.1093.
    PubMed     Abstract available
    
    
    March 2026
22. KRISHNA J, Khan Z, Chandra Y, Sivakumar S, et al
    Unveiling glomerulonephritis in the Pacific: a Fijian cohort study.
    J Nephrol. 2026 Mar 16:aajaf035. doi: 10.1093.
    PubMed     Abstract available
    
    
    February 2026
23. HUANG J, Xiao T, Zhang J, Li Y, et al
    Ambrisentan as adjunctive therapy for IgA nephropathy: a retrospective single-center analysis.
    J Nephrol. 2026 Feb 27:aajaf052. doi: 10.1093.
    PubMed     Abstract available
    
    
    November 2025
24. WANG R, Sun T, Shi Z, Fang X, et al
    Sustained renal response with belimumab in children with new-onset lupus nephritis.
    J Nephrol. 2025 Nov 13. doi: 10.1007/s40620-025-02397.
    PubMed     Abstract available
    
    
    October 2025
25. LEE YJ, Lee J, Ahn SM, Oh JS, et al
    Factors associated with pauci-immune glomerulonephritis in patients undergoing kidney biopsy with positive anti-neutrophil cytoplasmic antibody results.
    J Nephrol. 2025 Oct 15. doi: 10.1007/s40620-025-02430.
    PubMed     Abstract available
    
    
    
26. DING Q, Xue C, Gao X, Tang X, et al
    Efficacy and safety of obinutuzumab on progressive IgA nephropathy: a case series.
    J Nephrol. 2025 Oct 9. doi: 10.1007/s40620-025-02423.
    PubMed     Abstract available
    
    
    
27. KASZYNSKA A, Kepska-Dzilinska M, Karakulska-Prystupiuk E, Perkowska-Ptasinska A, et al
    Kidney failure in the course of focal segmental glomerulonephritis in a patient after alloHSCT - a case study and review of the literature.
    J Nephrol. 2025 Oct 7. doi: 10.1007/s40620-025-02375.
    PubMed     Abstract available
    
    
    September 2025
28. WATANABE-KUSUNOKI K, Nakazawa D, Ohigashi H, Tsuji T, et al
    Membranous nephropathy preceding Bing-Neel syndrome: successful treatment with tirabrutinib.
    J Nephrol. 2025 Sep 26. doi: 10.1007/s40620-025-02401.
    PubMed     Abstract available
    
    
    
29. BENVENUTI F, Proglio M, Rigno M, Sorbo D, et al
    Iptacopan/LNP023 and rituximab as rescue therapy in a patient with systemic lupus erythematosus-associated atypical haemolytic uraemic syndrome.
    J Nephrol. 2025 Sep 25. doi: 10.1007/s40620-025-02425.
    PubMed     Abstract available
    
    
    
30. PALMA RH, Soares RGL, Meinerz G, Keitel E, et al
    Current epidemiological overview of glomerulonephritis in Latin America: a systematic literature review.
    J Nephrol. 2025 Sep 16. doi: 10.1007/s40620-025-02418.
    PubMed     Abstract available
    
    
    
31. PACKBIERS M, Hahm A, Riebeling T, Brasen JH, et al
    Treatment of recurrent IgA nephropathy after kidney transplantation with targeted-release budesonide - a case report.
    J Nephrol. 2025 Sep 12. doi: 10.1007/s40620-025-02405.
    PubMed     Abstract available
    
    
    
32. VISWANATHAN S, Seshadri J, Kurien AA, Palani Baskar HD, et al
    An observational study on mesangial C4d staining as a prognostic tool in IgA nephropathy.
    J Nephrol. 2025 Sep 9. doi: 10.1007/s40620-025-02410.
    PubMed     Abstract available
    
    
    August 2025
33. EBRAHIMI N, Geetha D, Reyes-Bahamonde J, Zuppan CW, et al
    Correction: Effective management of lupus nephritis using a novel combination therapy with low-dose steroids: a case report.
    J Nephrol. 2025 Aug 26. doi: 10.1007/s40620-025-02408.
    PubMed    
    
    
    
34. EBRAHIMI N, Geetha D, Reyes-Bahamonde J, Zuppan CW, et al
    Effective management of lupus nephritis using a novel combination therapy with low-dose steroids: a case report.
    J Nephrol. 2025 Aug 8. doi: 10.1007/s40620-025-02361.
    PubMed     Abstract available
    
    
    July 2025
35. PONTICELLI C, Moroni G
    Correction: Targeting autophagy in autoimmune glomerular diseases.
    J Nephrol. 2025 Jul 29. doi: 10.1007/s40620-025-02360.
    PubMed    
    
    
    
36. LI J, Tai H, Yang B, Xu J, et al
    Efficacy and safety of TRF-budesonide in IgA nephropathy treatment: a meta-analysis.
    J Nephrol. 2025 Jul 28. doi: 10.1007/s40620-025-02341.
    PubMed     Abstract available
    
    
    
37. BADAWI MH, Nagy E, Wafa EW, El-Husseini A, et al
    Impact of SGLT2i on bone health in patients with lupus nephritis: randomized double blinded placebo-controlled clinical trial.
    J Nephrol. 2025 Jul 13. doi: 10.1007/s40620-025-02351.
    PubMed     Abstract available
    
    
    
38. HIRANO K, Ikenoue T, Seki T, Komukai S, et al
    Development and validation of personalized risk prediction models for patients with IgA nephropathy: a nationwide multicenter cohort study.
    J Nephrol. 2025 Jul 11. doi: 10.1007/s40620-025-02338.
    PubMed     Abstract available
    
    
    
39. QI F, Zeng HQ, Zhu L, Zhou P, et al
    Efficacy of methylprednisolone pulse therapy in Chinese children with IgA vasculitis-associated nephritis (IgAVN).
    J Nephrol. 2025;38:1565-1572.
    PubMed     Abstract available
    
    
    June 2025
40. DECAESTECKER A, Daniel A, Malbranque Z, Wayolle N, et al
    Crescentic glomerulonephritis associated with myelodysplatic syndrome and visceral leishmaniasis.
    J Nephrol. 2025 Jun 19. doi: 10.1007/s40620-025-02329.
    PubMed     Abstract available
    
    
    
41. GOGGINS E, DeLaat A, Barr B, Taliercio J, et al
    Clinical uptake of an antigen-based approach to membranous nephropathy: a survey of general nephrologists and glomerular disease experts.
    J Nephrol. 2025 Jun 11. doi: 10.1007/s40620-025-02313.
    PubMed     Abstract available
    
    
    May 2025
42. ISHIGAKI S, Takei H, Hiramoto K, Kaneko Y, et al
    Plasma cell-rich interstitial nephritis without glomerulonephritis in granulomatosis with polyangiitis.
    J Nephrol. 2025 May 30. doi: 10.1007/s40620-025-02318.
    PubMed    
    
    
    April 2025
43. MATHEW GG
    Molecular markers or clinical end points? What is the optimal monitoring tool for low-dose rituximab in membranous nephropathy in resource-limited settings?
    J Nephrol. 2025 Apr 7. doi: 10.1007/s40620-025-02273.
    PubMed     Abstract available
    
    
    
44. TANG C, Si FL, Chen P, Hou WY, et al
    Effectiveness and safety of finerenone in non-diabetic patients with IgA nephropathy.
    J Nephrol. 2025 Apr 1. doi: 10.1007/s40620-025-02240.
    PubMed    
    
    
    March 2025
45. XU L, Wu C, Li G
    Prevalence and trend of biopsy-proven IgA nephropathy in China: a systematic review.
    J Nephrol. 2025 Mar 26. doi: 10.1007/s40620-025-02261.
    PubMed     Abstract available
    
    
    
46. CLAUDIO P, Gabriella M
    Targeting autophagy in autoimmune glomerular diseases.
    J Nephrol. 2025 Mar 19. doi: 10.1007/s40620-025-02267.
    PubMed     Abstract available
    
    
    
47. MAHMOUD NB, Sahtout W, Ghabi F, Salem MB, et al
    Prognostic value of C3-exclusive deposits in post-infectious glomerulonephritis in adults: an observational cohort in Tunisia.
    J Nephrol. 2025 Mar 7. doi: 10.1007/s40620-025-02262.
    PubMed    
    
    
    
48. BONELLI GD, Sciascia S, Calatroni M, L'imperio V, et al
    Clinical presentation, outcomes and risk of relapses of lupus podocytopathy in a multicentre Italian cohort.
    J Nephrol. 2025;38:643-653.
    PubMed     Abstract available
    
    
    
49. EISINGER F, Neumann M, Worn M, Fritsche A, et al
    Comparison of GFR estimation in patients with diabetes mellitus using the EKFC and CKD-EPI equations.
    J Nephrol. 2025;38:707-716.
    PubMed     Abstract available
    
    
    February 2025
50. SRIDHARAN K, Gopal B, Wilson S, Pham A, et al
    Obinutuzumab in Rituximab-resistant and recurrent membranous nephropathy: a case-series.
    J Nephrol. 2025 Feb 20. doi: 10.1007/s40620-025-02224.
    PubMed     Abstract available
    
    
    
51. UMEZAWA Y, Aoki R, Ichikawa D, Suzuki Y, et al
    Glomerular galactose-deficient IgA1 and apoptosis inhibitor of macrophage staining in secondary IgA nephropathy associated with alcoholic cirrhosis.
    J Nephrol. 2025 Feb 13. doi: 10.1007/s40620-025-02213.
    PubMed     Abstract available
    
    
    January 2025
52. KANG D, Zhang M, Chen Z, Zheng Z, et al
    Clinicopathological characteristics and prognosis of lupus nephritis patients with positive anti-ribonucleoprotein antibodies.
    J Nephrol. 2025 Jan 20. doi: 10.1007/s40620-024-02177.
    PubMed     Abstract available
    
    
    December 2024
53. JAFRY NH, Butt N, Mubarak M, Akhtar SF, et al
    Anti-glomerular basement membrane disease complicated by malaria during pregnancy with successful maternal and fetal outcomes: a case report.
    J Nephrol. 2024;37:2655-2660.
    PubMed     Abstract available
    
    
    November 2024
54. YANG M, Liu X, Chen Y, Chen X, et al
    Validation and modification of renal risk score for prediction of long-term kidney survival in patients with MPO-ANCA-associated glomerulonephritis.
    J Nephrol. 2024 Nov 22. doi: 10.1007/s40620-024-02134.
    PubMed     Abstract available
    
    
    
55. KANBAY M, Ozbek L, Guldan M, Copur S, et al
    Post-transplant IgA nephropathy: a rapidly evolving field of kidney transplant medicine.
    J Nephrol. 2024 Nov 20. doi: 10.1007/s40620-024-02149.
    PubMed     Abstract available
    
    
    
56. QUEYREL-MORANNE V, Daniel L, Moranne O
    Focal segmental glomerulosclerosis in a native African patient with systemic lupus erythematosus.
    J Nephrol. 2024 Nov 12. doi: 10.1007/s40620-024-02106.
    PubMed    
    
    
    October 2024
57. ELAHI T, Ahmed S, Ahmed E, Mubarak M, et al
    Clinicopathological characteristics and outcomes of adult patients with idiopathic membranoproliferative glomerulonephritis according to an immunofluorescence-based classification.
    J Nephrol. 2024 Oct 14. doi: 10.1007/s40620-024-02083.
    PubMed     Abstract available
    
    
    
58. ZHANG Q, Zhou F, Zhao Y, Luo C, et al
    The uncertain correlation of ANCAs in patients with lupus nephritis and crescents, an experience from Chinese centers.
    J Nephrol. 2024 Oct 10. doi: 10.1007/s40620-024-02085.
    PubMed     Abstract available
    
    
    
59. BARAGETTI I, Del Vecchio L, Ferrario F, Alberici F, et al
    The safety of corticosteroid therapy in IGA nephropathy: analysis of a real-life Italian cohort.
    J Nephrol. 2024 Oct 6. doi: 10.1007/s40620-024-02071.
    PubMed     Abstract available
    
    
    
60. HERNANDEZ-ANDRADE A, Nordmann-Gomes A, Juarez-Cuevas B, Zavala-Miranda MF, et al
    Urine epidermal growth factor as a biomarker for kidney function recovery and prognosis in glomerulonephritis with severe kidney function impairment.
    J Nephrol. 2024 Oct 4. doi: 10.1007/s40620-024-02068.
    PubMed     Abstract available
    
    
    July 2024
61. YANG T, Shi Y, Wang Y, Feng Y, et al
    Hydroxychloroquine blood concentrations and effects in Chinese patients with IgA nephropathy.
    J Nephrol. 2024 Jul 24. doi: 10.1007/s40620-024-02029.
    PubMed     Abstract available
    
    
    
62. BALTU D, Serin O, Aksu T, Hizarcioglu Gulsen H, et al
    Membranoproliferative glomerulonephritis in a patient with lysinuric protein intolerance: lesson for the clinical nephrologist.
    J Nephrol. 2024 Jul 17. doi: 10.1007/s40620-024-02018.
    PubMed    
    
    
    
63. PERNA A, Campise M, Alfieri CM, Regalia A, et al
    Kidney transplantation in patients with ANCA-associated vasculitis is associated with a high incidence of post-transplant cancer.
    J Nephrol. 2024;37:1611-1619.
    PubMed     Abstract available
    
    
    June 2024
64. SARA M, Anna S, Lorenzo B, Valentina B, et al
    Macrophage activation syndrome secondary to systemic lupus erythematosus: lesson for the clinical nephrologist.
    J Nephrol. 2024 Jun 28. doi: 10.1007/s40620-024-01997.
    PubMed    
    
    
    
65. RATNAYAKE C, Crombie T, Fraenkel M, McMahon LP, et al
    Haemoptysis in a stable kidney transplant patient previously seropositive for anti-GBM and ANCA glomerulonephritis.
    J Nephrol. 2024 Jun 18. doi: 10.1007/s40620-024-01993.
    PubMed    
    
    
    
66. LIM RS, Yeo SC
    EXternal validation of international IgA nephropathy prediction tool in a Singapore CohorT (EXIST Study).
    J Nephrol. 2024 Jun 13. doi: 10.1007/s40620-024-01985.
    PubMed    
    
    
    
67. LIU L, de Leeuw K, der Meer BD, van Goor H, et al
    Expression of myxovirus resistance protein A in lupus nephritis and other glomerular nephropathies.
    J Nephrol. 2024 Jun 5. doi: 10.1007/s40620-024-01971.
    PubMed    
    
    
    
68. CUGNO M, Mancuso MC, Depetri F, Peyvandi F, et al
    IgM autoantibodies to complement factor H in C3 glomerulopathy.
    J Nephrol. 2024 Jun 1. doi: 10.1007/s40620-024-01961.
    PubMed    
    
    
    May 2024
69. NAGARAJAH S, Saleh QW, Rasmussen M, Tepel M, et al
    Long non-coding RNA MGAT3 in kidney transplant recipients with immunoglobulin A nephropathy.
    J Nephrol. 2024;37:1133-1135.
    PubMed    
    
    
    
70. CETINKAYA H, Gursu M, Yazici H, Cebeci E, et al
    Could mesangial C3 deposition be an independent prognostic marker in immunoglobulin A nephropathy?
    J Nephrol. 2024;37:923-932.
    PubMed     Abstract available
    
    
    April 2024
71. DAVIES E, Chetwynd A, McDowell G, Rao A, et al
    The current use of proteomics and metabolomics in glomerulonephritis: a systematic literature review.
    J Nephrol. 2024 Apr 30. doi: 10.1007/s40620-024-01923.
    PubMed     Abstract available
    
    
    
72. SHAHEEN M, Bharat A, Friedman AN, Guo S, et al
    ALECT2 amyloidosis with concurrent IgG4-related interstitial nephritis, membranous nephropathy and diabetic kidney disease: a case report and literature review.
    J Nephrol. 2024 Apr 17. doi: 10.1007/s40620-024-01924.
    PubMed     Abstract available
    
    
    March 2024
73. ROBERT JT, Rajaram A, Fiset PO, Bernard C, et al
    Class V lupus nephritis recurrence with histologic resolution in a kidney transplant recipient on a pregnancy-adapted immunosuppression protocol: a lesson for the clinical nephrologist.
    J Nephrol. 2024 Mar 26. doi: 10.1007/s40620-024-01920.
    PubMed    
    
    
    
74. HU D, Wang Z, Wang S, Li Y, et al
    Lymphatic vessels in patients with crescentic glomerulonephritis: association with renal pathology and prognosis.
    J Nephrol. 2024 Mar 25. doi: 10.1007/s40620-024-01903.
    PubMed     Abstract available
    
    
    
75. REN W, Sun J, Zhang L, He W, et al
    Significance of the total renal chronicity score in predicting renal outcome in PLA2R-associated membranous nephropathy.
    J Nephrol. 2024 Mar 21. doi: 10.1007/s40620-024-01893.
    PubMed     Abstract available
    
    
    
76. ARNAERT S, Schepens N, Deleu L, Malfait T, et al
    Case report: renal recovery in Goodpasture's syndrome treated with rituximab.
    J Nephrol. 2024 Mar 1. doi: 10.1007/s40620-024-01892.
    PubMed     Abstract available
    
    
    
77. VAZ DE CASTRO PAS, Amaral AA, Almeida MG, Selvaskandan H, et al
    Examining the association between serum galactose-deficient IgA1 and primary IgA nephropathy: a systematic review and meta-analysis.
    J Nephrol. 2024 Mar 1. doi: 10.1007/s40620-023-01874.
    PubMed     Abstract available
    
    
    February 2024
78. CHRISTODOULOU M, Moysidou E, Lioulios G, Stai S, et al
    The prognostic value of two histopathologic classification models of ANCA-associated glomerulonephritis: a prospective study.
    J Nephrol. 2024 Feb 12. doi: 10.1007/s40620-023-01855.
    PubMed     Abstract available
    
    
    
79. OCHIAI S, Kikuchi M, Kaikita K, Fujimoto S, et al
    Rapidly progressive glomerulonephritis due to IgA nephropathy accompanied by collagenofibrotic glomerulopathy. A nephrology picture.
    J Nephrol. 2024 Feb 6. doi: 10.1007/s40620-023-01875.
    PubMed    
    
    
    January 2024
80. TRIMARCHI H, Fervenza FC, Coppo R
    Points of view in nephrology: personalized management of IgA nephropathy, beyond KDIGO.
    J Nephrol. 2024 Jan 18. doi: 10.1007/s40620-023-01833.
    PubMed     Abstract available
    
    
    
81. HE WJ, Wang J, Liu N, Li GY, et al
    The efficacy and safety of hydroxychloroquine versus leflunomide in patients with IgA nephropathy: a single-center experience.
    J Nephrol. 2024 Jan 16. doi: 10.1007/s40620-023-01839.
    PubMed     Abstract available
    
    
    December 2023
82. SCHENA FP, Cox SN
    Correction to: Is it time for personalized therapy in IgA nephropathy patients?
    J Nephrol. 2023 Dec 8. doi: 10.1007/s40620-023-01861.
    PubMed    
    
    
    
83. BOUSSETTA A, Jellouli M, Hajji M, Rekaya S, et al
    A membranous nephropathy in a 5 year-old boy: and if that's not all? A nephrology quiz.
    J Nephrol. 2023 Dec 6. doi: 10.1007/s40620-023-01821.
    PubMed    
    
    
    November 2023
84. ALBERTAZZI V, Fontana F, Giberti S, Aiello V, et al
    Primary membranous nephropathy in the Italian region of Emilia Romagna: results of a multicenter study with extended follow-up.
    J Nephrol. 2023 Nov 13. doi: 10.1007/s40620-023-01803.
    PubMed     Abstract available
    
    
    
85. BANJONGJIT A, Thammathiwat T, Townamchai N, Kanjanabuch T, et al
    SARS-CoV-2 infection associated with antineutrophil cytoplasmic antibody (ANCA)-associated glomerulonephritis (ANCA-GN): a systematic review and two case reports.
    J Nephrol. 2023 Nov 6. doi: 10.1007/s40620-023-01777.
    PubMed     Abstract available
    
    
    
86. RUSSWURM M, Kortus-Goetze B, Maier-Giebing T, Groene HJ, et al
    General prognostic models may neglect vulnerable subgroups in ANCA-associated vasculitis.
    J Nephrol. 2023;36:2269-2280.
    PubMed     Abstract available
    
    
    
87. GOTO K, Imaizumi T, Hamada R, Ishikura K, et al
    Renal pathology in adult and paediatric population of Japan: review of the Japan renal biopsy registry database from 2007 to 2017.
    J Nephrol. 2023;36:2257-2267.
    PubMed     Abstract available
    
    
    
88. XIONG L, Liu L, Tao Y, Guo H, et al
    Clinical significance of IgM and C3 deposition in children with primary immunoglobulin A nephropathy.
    J Nephrol. 2023;36:2213-2222.
    PubMed     Abstract available
    
    
    
89. RAO IR, Kolakemar A, Shenoy SV, Prabhu RA, et al
    Hydroxychloroquine in nephrology: current status and future directions.
    J Nephrol. 2023;36:2191-2208.
    PubMed     Abstract available
    
    
    
90. SCURT FG, Hirschfeld V, Ganz M, Mertens PR, et al
    Low levels of complement factor C3 at diagnosis can predict outcome in antineutrophil antibody associated vasculitis.
    J Nephrol. 2023;36:2281-2293.
    PubMed     Abstract available
    
    
    
91. WANG F, Jin Y, Zhou F, Luo L, et al
    Urinary isomorphic red blood cells for the prediction of disease severity and renal outcomes in MPO-ANCA-associated vasculitis: a retrospective cohort study.
    J Nephrol. 2023;36:2295-2304.
    PubMed     Abstract available
    
    
    
92. ROCCATELLO D, Careddu A, Ferro M, Naretto C, et al
    The steroid-sparing effects of a mycophenolate mofetil-based regimen in the management of immunoglobulin A nephropathy in patients with histologically active lesions: A comparison with a control cohort receiving conventional therapy.
    J Nephrol. 2023;36:2223-2231.
    PubMed     Abstract available
    
    
    
93. ALVAREZ L, Kambham N, Su R
    Renal improvement and remission in a patient with refractory ANCA-associated vasculitis treated with avacopan.
    J Nephrol. 2023;36:2365-2370.
    PubMed     Abstract available
    
    
    October 2023
94. LIU Z, Wan C, Cao Y, Liu S, et al
    Distribution spectrum and clinical significance of glomerular exostosin (EXT1) deposits in PLA2R-positive membranous nephropathy.
    J Nephrol. 2023 Oct 26. doi: 10.1007/s40620-023-01779.
    PubMed     Abstract available
    
    
    
95. PALA C, Parenti E, Vizzini G, Gianfreda D, et al
    Thrombotic microangiopathy due to primary antiphospholipid syndrome: successful treatment with eculizumab.
    J Nephrol. 2023 Oct 17. doi: 10.1007/s40620-023-01789.
    PubMed     Abstract available
    
    
    
96. MONGERA N, Passler W, Sethi S, Kozakowski N, et al
    A case of protocadherin FAT1-positive membranous nephropathy secondary to hematopoietic stem-cell transplantation.
    J Nephrol. 2023 Oct 10. doi: 10.1007/s40620-023-01786.
    PubMed    
    
    
    September 2023
97. PAOLO SF, Natasha CS
    Is it time for personalized therapy in IgA nephropathy patients?
    J Nephrol. 2023 Sep 22. doi: 10.1007/s40620-023-01745.
    PubMed    
    
    
    
98. AI S, Yan X, Zhao X, Ye W, et al
    Malignancy-associated membranous nephropathy: focus on diagnosis and treatment.
    J Nephrol. 2023 Sep 15. doi: 10.1007/s40620-023-01751.
    PubMed     Abstract available
    
    
    
99. BAIER E, Kluge IA, Hakroush S, Tampe B, et al
    Low hemoglobin levels are associated with Bowman's capsule rupture and peritubular capillaritis in ANCA-associated renal vasculitis: a link of vascular injury to anemia?
    J Nephrol. 2023 Sep 7. doi: 10.1007/s40620-023-01748.
    PubMed     Abstract available
    
    
    
100. DIRIM AB, Agargun BF, Hurdogan O, Ozluk Y, et al
     Two cases of IgA nephropathy after splenectomy: spleen as a silent culprit in the pathogenesis of IgA nephropathy.
     J Nephrol. 2023 Sep 4. doi: 10.1007/s40620-023-01764.
     PubMed    
     
     
     June 2023
101. WATANABE H, Yamana H, Okada A, Matsui H, et al
     Therapeutic plasma exchange for anti-glomerular basement membrane disease with dialysis-dependent kidney failure without diffuse alveolar hemorrhage.
     J Nephrol. 2023 Jun 24. doi: 10.1007/s40620-023-01695.
     PubMed     Abstract available
     
     

Thank you for your interest in scientific medicine.

AMEDEO Autoimmune Disorders is free of charge. Privacy / Datenschutzerklärung | Imprint / Impressum